 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...132133134135136137138139140141142143144» |
- ||||| duligotuzumab (MEHD7945A) / Roche
New P2 trial, Metastases: A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck (clinicaltrials.gov) - Apr 11, 2012
P2, N=122, Active, not recruiting, Sponsor: Genentech
- ||| tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Enrollment closed, Combination therapy, Metastases: ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 11, 2012
P1/2, N=150, Active, not recruiting, Sponsor: Daiichi Sankyo Inc.
Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: EMR 200068-007: EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Apr 5, 2012
P1, N=13, Terminated, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting N=30 --> 13
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Surgery, Metastases: EMR 622022237: Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (clinicaltrials.gov) - Apr 4, 2012
P2, N=121, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
N=30 --> 13 Active, not recruiting --> Recruiting
- |||| Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion, Metastases: A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 3, 2012
P2, N=94, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Apr 3, 2012
P2, N=63, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer (clinicaltrials.gov) - Apr 3, 2012
P3, N=766, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, New P2 trial: Tumour markers response to chemotherapy in patients with colorectal liver metastases Marcatori di risposta alla chemioterapia in pazienti con metastasi epatiche colorettali (EUDRACT) - Apr 2, 2012
P2, N=300, Ongoing, Sponsor: ISTITUTI FISIOTERAPICI OSPITALIERI
- |||| dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Trial completion, Combination therapy, Metastases: Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) (clinicaltrials.gov) - Apr 2, 2012
P2, N=560, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Surgery: PETACC-8: Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery (clinicaltrials.gov) - Apr 1, 2012
P3, N=2564, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Active, not recruiting --> Completed N=2000 --> 2564
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: A randomized phase II study of FOLFORI plus or not CETUXIMAB in elderly advanced colorectal cancer patients. Studio randomizatto di fase II con FOLFIRI piu' CETUXIMAB o FOLFIRI da solo in pazienti anziani affetti da tumore colo-rettale avanzato. (EUDRACT) - Apr 1, 2012
P2, N=74, Ongoing, Sponsor: AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Surgery: PETACC-8: Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery (clinicaltrials.gov) - Apr 1, 2012
P3, N=2564, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
N=2000 --> 2564 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer (clinicaltrials.gov) - Mar 29, 2012
P2, N=33, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Completed N=25 --> 33
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer (clinicaltrials.gov) - Mar 29, 2012
P2, N=33, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=25 --> 33 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: Pharmacokinetics and Metabolic Activation of Capecitabine (clinicaltrials.gov) - Mar 28, 2012
P2, N=24, Recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
- albumin-bound paclitaxel / Generic mfg.
New P2 trial, IO biomarker, Metastases: Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer (clinicaltrials.gov) - Mar 27, 2012
P2, N=29, Active, not recruiting, Sponsor: Washington University School of Medicine
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P4 trial, Combination therapy, Metastases: Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 26, 2012
P4, N=150, Recruiting, Sponsor: Xu jianmin
- Cilcane (cilengitide) / Iceni Pharma, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination: Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma (clinicaltrials.gov) - Mar 20, 2012
P2, N=12, Terminated, Sponsor: Bart Neyns
Active, not recruiting --> Completed Suspended --> Terminated; Results of the phase III RTOG0525 trial made the manufacturer of cilengitide decide to end their support to the trial
- Cilcane (cilengitide) / Iceni Pharma, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma (clinicaltrials.gov) - Mar 20, 2012
P2, N=12, Terminated, Sponsor: Bart Neyns
Suspended --> Terminated; Results of the phase III RTOG0525 trial made the manufacturer of cilengitide decide to end their support to the trial N=108 --> 12
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 17, 2012
P2, N=100, Completed, Sponsor: Herlev Hospital
N=108 --> 12 Recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment open, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Mar 15, 2012
P1, N=216, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Enrollment open: S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride (clinicaltrials.gov) - Mar 13, 2012
P=N/A, N=140, Recruiting, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P4 trial: Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux (clinicaltrials.gov) - Mar 11, 2012
P4, N=500, Recruiting, Sponsor: University of Heidelberg Medical Center
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
New P1 trial, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Mar 11, 2012
P1, N=216, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial withdrawal, Metastases: Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy (clinicaltrials.gov) - Mar 4, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Metastases: Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy (clinicaltrials.gov) - Mar 4, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Withdrawn Initiation date: Jul 2008 --> Jul 2009
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy (clinicaltrials.gov) - Mar 4, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Initiation date: Jul 2008 --> Jul 2009 N=95 --> 0
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, alisertib (MLN8237) / Puma
New P1 trial, Combination therapy, Metastases: MLN8237 in Head and Neck Cancer (clinicaltrials.gov) - Feb 27, 2012
P1, N=9, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Surgery, Metastases: COMBATAC: Combined Anticancer Treatment of Advanced Colon Cancer (clinicaltrials.gov) - Feb 26, 2012
P2, N=60, Recruiting, Sponsor: University of Regensburg
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 22, 2012
P2, N=169, Active, not recruiting, Sponsor: Cheryl Pugh
N=95 --> 0 Recruiting --> Active, not recruiting
- TNFerade (golnerminogene pradenovec) / Precigen
Trial completion: Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer (clinicaltrials.gov) - Feb 21, 2012
P1/2, N=0, Completed, Sponsor: GenVec
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- robatumumab (SCH 717454) / Merck (MSD)
Trial termination, Combination therapy, Metastases: Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) (clinicaltrials.gov) - Feb 20, 2012
P1b/2, N=15, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Completed --> Terminated; This study was terminated for business reasons.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Metastases: Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Feb 18, 2012
P2, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Completed --> Terminated; This study was terminated for business reasons. Initiation date: Sep 2011 --> Feb 2012
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Feb 18, 2012
P2, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Initiation date: Sep 2011 --> Feb 2012 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial initiation date: Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab (clinicaltrials.gov) - Feb 14, 2012
P=N/A, N=40, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Initiation date: Jul 2011 --> Jan 2012
- Imprime PGG (odetiglucan) / HiberCell
Enrollment change, Combination therapy, Metastases: Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer (clinicaltrials.gov) - Feb 13, 2012
P=N/A, N=18, Completed, Sponsor: Biothera
Initiation date: Jul 2011 --> Jan 2012 N=56 --> 18
- | Imprime PGG (odetiglucan) / HiberCell
Trial completion, Combination therapy, Metastases: Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer (clinicaltrials.gov) - Feb 13, 2012
P=N/A, N=18, Completed, Sponsor: Biothera
N=56 --> 18 Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Trial withdrawal, Metastases: Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer (clinicaltrials.gov) - Feb 13, 2012
P=N/A, N=0, Withdrawn, Sponsor: Thomas Jefferson University
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer (clinicaltrials.gov) - Feb 13, 2012
P=N/A, N=0, Withdrawn, Sponsor: Thomas Jefferson University
Recruiting --> Withdrawn N=56 --> 0
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: A Study of Mitomycin C, Irinotecan, and Cetuximab (clinicaltrials.gov) - Feb 13, 2012
P2, N=13, Completed, Sponsor: University of Michigan Cancer Center
N=56 --> 0 N=39 --> 13
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: A Study of Mitomycin C, Irinotecan, and Cetuximab (clinicaltrials.gov) - Feb 13, 2012
P2, N=13, Completed, Sponsor: University of Michigan Cancer Center
N=39 --> 13 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, IO biomarker, Metastases: Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab (clinicaltrials.gov) - Feb 6, 2012
P2, N=88, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 1, 2012
P2, N=39, Active, not recruiting, Sponsor: New York University School of Medicine
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jan 31, 2012
P2, N=75, Active, not recruiting, Sponsor: University of Southern California
Recruiting --> Active, not recruiting N=53 --> 75
- ||||| Zelboraf (vemurafenib) / Roche
New P2 trial: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers (clinicaltrials.gov) - Jan 31, 2012
P2, N=160, Recruiting, Sponsor: Hoffmann-La Roche
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jan 31, 2012
P2, N=75, Active, not recruiting, Sponsor: University of Southern California
N=53 --> 75 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: ATIP: Safety and Efficacy Therapy of Gemcitabine and Erbitux (clinicaltrials.gov) - Jan 31, 2012
P2, N=76, Completed, Sponsor: Carmen Schade-Brittinger
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer (clinicaltrials.gov) - Jan 31, 2012
P3, N=750, Completed, Sponsor: Dutch Colorectal Cancer Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Combination therapy, Metastases: A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis (clinicaltrials.gov) - Jan 30, 2012
P2, N=8, Terminated, Sponsor: Austrian Breast & Colorectal Cancer Study Group
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Colorectal Cancer (CRC) Cetuximab Elderly Frail (clinicaltrials.gov) - Jan 29, 2012
P2, N=150, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC